CDXI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 Dec 2023 @ 09:38):

Stats
Today's Volume	1.00
Average Volume	0.00
Market Cap	4.00
EPS	$-1.740 ( 2021-05-14 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2014-02-24	Paulson Capital (delaware) Corp.	Buy	500 000	Common Stock
2014-02-24	Paulson Cardax Investments 1 Llc	Buy	500 000	Common Stock
2014-02-07	Paulson Capital (delaware) Corp.	Buy	1 068 477	Warrants (right to buy)
2014-02-07	Paulson Cardax Investments 1 Llc	Buy	1 068 477	Warrants (right to buy)
2014-02-07	Paulson Capital (delaware) Corp.	Buy	0	Common Stock

INSIDER POWER
0.00
Last 4 transactions
Buy: 3 136 954 \| Sell: 0

Volume Correlation

Long: -0.01 (neutral)

Short: 0.00 (neutral)

Signal:(99.872) Neutral

Cardax, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cardax, Inc. Correlation - Currency/Commodity

0.00
( neutral )

Cardax, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

FY	2020
Revenue:	$538 946
Gross Profit:	$342 816 (63.61 %)
EPS:	$-6.79

FY	2019
Revenue:	$710 949
Gross Profit:	$365 556 (51.42 %)
EPS:	$-7.49

Financial Reports:

No articles found.

Cardax, Inc.

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.